目录产品 » SARS-CoV-2 Spike protein (RBD, His Tag)
Manual
SDS
COAs

SARS-CoV-2 Spike protein (RBD, His Tag)

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.
￥3800
Z03479

产品简介
Species SARS-CoV-2
Protein Construction
Spike RBD (Pro330-Ser530)
Accession # P0DTC2		 Poly-His
N-term C-term
Purity > 90% as analyzed by SDS-PAGE
Biological Activity SARS-CoV-2 Spike protein (RBD, His Tag) can bind with Human ACE2 in functional ELISA assay.
Expression System Sf9 insect cells
Theoretical Molecular Weight 25 kDa
Formulation Supplied as a solution in PBS pH 7.2.
Concentration Please refer to the COA for the specific lot.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at -20°C or below. Avoid repeated freeze-thaw cycles.
返回

图例
SARS-CoV-2 Spike Protein (RBD, His Tag)

»

SARS-CoV-2 Spike Protein (RBD, His Tag)

»

SARS-CoV-2 Spike Protein (RBD, His Tag)

Immobilized ACE-2 Fc Chimera, Human (Cat. No. Z03484) at 2 μg/mL can bind SARS-CoV-2 Spike protein (RBD, His Tag) (Cat. No. Z03479) with a serial dilution.
THETM His Tag Antibody [HRP], mAb, Mouse (Cat.No.A00612) is used as a secondary antibody (0.1 μg/mL). »

SARS-CoV-2 Spike Protein (RBD, His Tag)

Lane 1: 1μg of SARS-CoV-2 Spike protein (RBD, His Tag), reducing(R)
Lane 2: 3μg of SARS-CoV-2 Spike protein (RBD, His Tag), reducing(R)
Lane 3: 5μg of SARS-CoV-2 Spike protein (RBD, His Tag), reducing(R)
Lane 4: 5μg of SARS-CoV-2 Spike protein (RBD, His Tag), non-reducing(NR)
> 95% as analyzed by SDS-PAGE »

<
>

技术背景
Target Background SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.
Synonyms SARS-CoV-2 SP RBD; 2019-nCoV RBD
返回

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


相关文献
Christine M Bradshaw, et al. Cutting Edge: Characterization of Low Copy Number Human Angiotensin-Converting Enzyme 2-Transgenic Mice as an Improved Model of SARS-CoV-2 Infection. J Immunol. (2024-02)
Narach Khorattanakulchai, et al. A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques. Front Plant Sci. (2022-09)
Krista G Freeman, et al. A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display. Microorganisms. (2021-11)
Thomas Güttler, et al. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. EMBO J. (2021-08)
Andrei Komarov, et al. Dual-Antigen System Allows Elimination of False Positive Results in COVID-19 Serological Testing. Diagnostics (Basel). (2021-01)
Qiang Zeng, et al. Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension. Front Immunol. (2020-12)
Balamurugan Shanmugaraj, et al. Monoclonal Antibodies B38 and H4 Produced in Neutralize SARS-CoV-2. Front Plant Sci. (2020-11)
Ripperger TJ, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity. (2020-11)
Wei-Chiao Huang, et al. SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination. Adv Mater. (2020)